Abstract
Background: CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) was the first immune checkpoint receptor clinically targeted for use in cancer treatm......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
